Accessibility Menu
Molecular Partners Ag logo

Molecular Partners Ag(NASDAQ) MOLN

Market Cap$164.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-77%
5 Year-80%
1 Year+14%
1 Month+9%
$4.29
-4.78%
-0.22Today
Molecular Partners Ag last closing stock price
MetricPriceDate
Last closeUSD 4.292026-09-01
Molecular Partners Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.17%USD 4.382026-08-25
1 month+9.03%USD 3.932026-07-31
3 month+6.33%USD 4.032026-06-03
Year to date-1.69%USD 4.362025-12-31
1 year+14.27%USD 3.752025-08-29
3 year-28.58%USD 6.002023-09-01
5 year-79.6%USD 21.002021-09-02
Since inception-77.1%USD 19.652021-06-16

Molecular Partners Ag Financials at a Glance

Market Cap

$164.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 0.00

Net Income (TTM)

-CHF 57.55M

EPS (TTM)

-$1.71

P/E Ratio

-2.50

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$4.29

Volume

968

Open

$4.38

Previous Close

$4.29

Daily Range

$4.29 - $4.38

52-Week Range

$3.53 - $5.36

Estimated Earnings Date

Oct 29, 2026

MOLN News

Arrow up, blocks

3 Stocks That Have Soared as the Market Sank: Are They Buys Now?

Keith SpeightsJan 28, 2022
A researcher studying a sample in a petri dish

Why Molecular Partners Stock Crushed the Market Today

Eric VolkmanJan 10, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Molecular Partners Ag

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm utilizes its proprietary DARPin® technology to develop a diverse pipeline of product candidates targeting various diseases.

Products and Services
  • Abicipar: A DARPin therapeutic in Phase III trials for eye diseases
  • MP0420: A multi-specific DARPin targeting SARS-CoV-2 for COVID-19
  • MP0310: An immuno-oncology candidate in Phase Ia clinical trials
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Partnerships with major pharmaceutical companies enhance development capabilities
  • Focus on innovative therapies positions the company for future growth
Financial Highlights
  • Cash and cash equivalents of CHF 67.7 million as of June 30, 2026
  • Operating loss of CHF 13.8 million reported in Q2 2026
  • Current ratio of 7.27 indicates strong liquidity position
Molecular Partners AG is strategically positioned in the biotechnology sector, focusing on innovative therapeutic solutions. The company's proprietary DARPin technology offers a unique approach to drug development, particularly in oncology and infectious diseases. With a robust pipeline and significant partnerships, the company is well-equipped to navigate the complexities of the biopharmaceutical landscape. Recent financial data indicates a solid liquidity position, although the company is currently operating at a loss as it invests heavily in research and development. The focus on advanced clinical trials and collaborations with established pharmaceutical companies may provide a pathway to future revenue generation and market success.
AI Generated • Aug 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

116.7

CEO

Patrick Amstutz, PhD

Website

www.molecularpartners.com

Headquarters

Schlieren, ZH 8952, CH

MOLN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-67.67%

Return on Capital

-69.21%

Return on Assets

-67.68%

Earnings Yield

-40.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$164.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

38.31M

Volume

968

Avg. Volume

4.53K

Financials (TTM)

Gross Profit

-CHF 11.24M

Operating Income

-CHF 57.99M

EBITDA

-CHF 55.42M

Operating Cash Flow

-CHF 51.51M

Capital Expenditure

-CHF 258.01K

Free Cash Flow

-CHF 51.77M

Cash & ST Invst.

CHF 67.69M

Total Debt

CHF 3.03M

Molecular Partners Ag Performance Analysis

Molecular Partners Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 198,520,4951760.8%
20232023-12-31CHF 7,831,732-96.1%
20242024-12-31CHF 5,643,446-27.9%
20252025-12-31CHF 0N/A
Molecular Partners Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Molecular Partners Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF 3.71N/A
20232023-12-31CHF -2.10N/A
20242024-12-31CHF -1.80-14.3%
20252025-12-31CHF -1.9910.5%
Molecular Partners Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3041.8%
Q42025-12-31-3.1%
Q12026-03-31-6.1%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 0.00

N/A

Gross Profit

-CHF 492.21K

N/A

Gross Margin

0.00%

N/A

Market Cap

$164.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.22M

N/A

Employees

134

N/A

Net Income

-CHF 13.79M

+32.4%

EBITDA

-CHF 13.33M

+32.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 67.69M

-40.9%

Total Debt

CHF 3.03M

+65.0%

Accounts Receivable

CHF 1.34M

-62.9%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 1.83M

+196.8%

Short Term Debt

CHF 1.21M

-1.3%

Return on Assets

-67.68%

N/A

Return on Invested Capital

-78.32%

N/A

Free Cash Flow

-CHF 10.83M

+17.9%

Operating Cash Flow

-CHF 10.81M

+17.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MISTMilestone Pharmaceuticals Inc.
$1.14-1.72%
NKTXNkarta, Inc.
$2.70-0.37%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$11.28+3.39%
PEPGPepGen Inc.
$3.12+4.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About MOLN

What is the current price of Molecular Partners Ag?

Molecular Partners Ag is trading at $4.29 per share.

What is the 52-week range for Molecular Partners Ag?

Over the past 52 weeks, Molecular Partners Ag has traded between $3.53 and $5.36.

How much debt does Molecular Partners Ag have?

As of the most recent reporting period, Molecular Partners Ag reported total debt of CHF 3.77M.

How much cash does Molecular Partners Ag have on hand?

Molecular Partners Ag reported CHF 84.21M in cash and cash equivalents in its most recent financial results.

What is Molecular Partners Ag’s dividend yield?

Molecular Partners Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services